第七届中国国际进口博览会(以下简称“进博会”)期间,全球肥胖症治疗领域的领导者诺和诺德携创新成果亮相,并凝聚多方力量,共启中国肥胖症防治新篇章。其中,全球首个且目前唯一用于长期体重管理的GLP-1RA周制剂诺和盈®(用于长期体重管理的司美格鲁肽注射液)迎来中国首秀,有望尽早惠及中国肥胖症患者。同时,诺和诺德将携手跨界合作伙伴,在健康教育、预防、诊断、治疗等环节全面发力,以多元化模式打造“驱动改变,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.